Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV/hMPV vaccine in adults 60+
NCT06134648Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SP0256 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV), sponsored by Sanofi. Primary endpoints: Presence of unsolicited systemic immediate adverse events at 30 minutes, Presence of solicited injection site or systemic reactions at 7 days and 5 more. Started Nov 2023; status: completed.
02
Drugs
SP0256
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT06134648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134648.